Acelrx Pharmaceuticals Inc SMA 200
What is the SMA 200 of Acelrx Pharmaceuticals Inc?
The SMA 200 of Acelrx Pharmaceuticals Inc is $1 -49.46%
What is the definition of SMA 200?
SMA 200 is an average stock price from the last 200 days calculated as an unweighted mean of the previous 200 stock closing prices.
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 200 of companies in the Health Care sector on NASDAQ compared to Acelrx Pharmaceuticals Inc
What does Acelrx Pharmaceuticals Inc do?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Companies with sma 200 similar to Acelrx Pharmaceuticals Inc
- Opko Health Inc has SMA 200 of $1 +17.86%
- Fullsun International Co has SMA 200 of HKD$1 -36.39%
- CYBERDYNE has SMA 200 of $1 +7.07%
- Galecto has SMA 200 of $1 +90.22%
- Dbt Sa has SMA 200 of €1 -91.33%
- Rifco has SMA 200 of CAD$1 -1.18%
- Acelrx Pharmaceuticals Inc has SMA 200 of $1 -49.46%
- Societe de Tayninh SA has SMA 200 of €1 -6.49%
- Clearside Biomedical Inc has SMA 200 of $1 +1.63%
- Rusoro Mining has SMA 200 of CAD$1 +0.82%
- Fox Marble PLC has SMA 200 of GBX1 +4.44%
- Ping An Healthcare and Technology has SMA 200 of $1 -31.96%
- Future Generation Global Investment has SMA 200 of AUD$1 +2.82%